Pulmonary arterial hypertension (PAH) is one of the cruelest diagnoses in cardiopulmonary medicine. The mean pulmonary artery pressure climbs above 20 mmHg at rest; the right ventricle hypertrophies and eventually fails. Without treatment, median survival clocks in at 2.8 years. Even on triple vasodilator therapy — phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclin analogues — the five-year mortality rate hovers near 50%. Why? Because these drugs dilate constricted vessels without reversing the structural obliteration of the pulmonary microvasculature. The intima thickens, the media hypertrophies, adventitial fibroblasts lay down collagen, and the lumen narrows inexorably. Mesenchymal stem cells (MSCs) are the first therapeutic candidate to target this pathological remodeling directly, and the 2026 preclinical data is the strongest signal yet that cell therapy may finally break the PAH therapeutic ceiling.
The Vascular Remodeling Problem: Why Vasodilators Aren’t Enough
PAH pathology converges on one destructive process: endothelial-to-mesenchymal transition (EndMT). Under the combined assault of BMPR2 mutations, chronic inflammation, shear stress, and metabolic dysregulation, pulmonary artery endothelial cells lose their endothelial identity — downregulating VE-cadherin, upregulating α-smooth muscle actin (α-SMA) — and morph into proliferative, matrix-secreting mesenchymal cells. A 2026 review in International Journal of Molecular Sciences (Chen X et al., DOI: 10.3390/ijms27114951) maps the molecular drivers: TGF-β/Smad signaling, hypoxia-inducible factors, Notch pathway activation, and epigenetic silencing of protective genes. The result is a self-perpetuating cycle: EndMT thickens the intima, which increases shear stress, which drives further EndMT. Vasodilators address the functional narrowing; they do not touch the structural narrowing. This is where MSCs enter the picture.
HO-1-Modified MSCs: A Multi-Pathway Attack on PAH
The standout 2026 paper comes from Chen R and colleagues at Guangdong Medical University, published in Stem Cells Translational Medicine (DOI: 10.1093/stcltm/szag036). Using spatial transcriptomics and single-cell RNA sequencing of human PAH lung tissue, the team demonstrated that heme oxygenase-1 (HO-1) is significantly downregulated in the pulmonary vascular endothelium of PAH patients. Reasoning that HO-1 — a stress-response enzyme with potent antioxidant, anti-inflammatory, and anti-apoptotic properties — could be the missing piece, they engineered human umbilical cord-derived MSCs to overexpress HO-1 (MSCs-HO-1) and tested them against unmodified MSCs in two gold-standard PAH models: monocrotaline (MCT)-induced and SU5416/hypoxia (SuHx).
The results were striking:
- Right ventricular systolic pressure (RVSP) fell significantly more with MSCs-HO-1 than with unmodified MSCs or HO-1 therapy alone.
- Right ventricular hypertrophy index (RVHI) — the ratio of right ventricle to left ventricle plus septum weight — was reduced, indicating real protection against decompensation.
- Survival improved in the MSCs-HO-1 group beyond what either monotherapy achieved.
- Vascular remodeling measured by α-SMA immunostaining of small pulmonary arteries showed reduced medial thickening and muscularization.
- Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-18) were suppressed while anti-inflammatory factors (IL-10, TGF-β, IL-4, IL-1Ra) increased.
- Endothelial function was restored — nitric oxide (NO) and prostacyclin (PGI2) levels normalized, and reactive oxygen species (ROS) dropped.
RNA sequencing of pulmonary artery endothelial cells pointed to the MAPK pathway as the central node through which MSCs-HO-1 exert endothelial protection. Critically, the combination of HO-1 overexpression with the MSC secretome produced synergistic effects — the modified cells were not just MSCs plus HO-1; they were a qualitatively different therapeutic. A companion study in Translational Research (DOI: 10.1016/j.trsl.2026.06.015) demonstrated that tracheal delivery of the same HO-1-modified UC-MSCs achieved therapeutic effect via MCP-1/ERK/NFAT pathway modulation, confirming route flexibility.
The SOCS3/STAT3 Axis: How MSCs Quiet the Adventitial Fibroblast
While endothelial protection grabs headlines, the adventitia — the outer layer of the pulmonary artery wall — is equally culpable in PAH. Pulmonary arterial adventitial fibroblasts (PAAFs) are activated early in the disease, proliferating and secreting collagen that stiffens the vessel wall. Wang J and colleagues at Guangzhou Medical University, reporting in Stem Cell Research & Therapy (DOI: 10.1186/s13287-025-04883-5), traced the mechanistic thread from MSC infusion to PAAF silencing.
In the MCT-rat model, a single early dose of MSCs (administered on day 1 post-induction) achieved what repeated dosing on days 7 and 14 could not match. The 28-day survival rate rose, RVSP declined, medial thickening regressed, and collagen deposition in the pulmonary arterioles was visibly reduced on histology. Critically, biodistribution tracking showed MSC retention in the lung peaked within 24 hours — the cells do not engraft long-term. Their benefit is paracrine, not structural. The team identified suppressor of cytokine signaling 3 (SOCS3) upregulation, with consequent inhibition of STAT3 phosphorylation, as the key molecular switch: MSCs secrete factors that upregulate SOCS3 in PAAFs, which in turn blocks STAT3-mediated pro-fibrotic gene expression. This is a clean mechanism — one protein target, one transcription factor, one fibroblast population — that explains how a transient cell infusion produces sustained anti-remodeling effects.
Mitochondrial Transplantation: Borrowing BM-MSC Organelles to Rescue the Right Ventricle
Perhaps the most conceptually elegant 2026 approach comes from Onofre MESF and the team at the Federal University of Rio de Janeiro (International Journal of Molecular Sciences, DOI: 10.3390/ijms27041761). Instead of infusing whole MSCs, they isolated functional mitochondria from bone marrow MSCs and transplanted them intravenously — alone and in combination with sildenafil — into MCT-induced PAH rats.
The rationale is grounded in mitochondrial biology: PAH is increasingly understood as a metabolic disease. Pulmonary artery smooth muscle cells in PAH exhibit a glycolytic shift reminiscent of the Warburg effect in cancer — suppressed oxidative phosphorylation, increased glucose uptake, resistance to apoptosis. The right ventricle, forced to pump against elevated afterload, undergoes its own metabolic decompensation with impaired Complex I and Complex IV activity. Transplanting healthy mitochondria could, in theory, rescue both compartments.
The data bore this out: mitochondrial transplantation alone reduced RVSP and arteriolar α-SMA content; combined with sildenafil, it additionally attenuated EndMT, improved Complex I-dependent respiration, and specifically restored Complex IV activity (which sildenafil alone did not touch). Plasma IL-6 and IL-1β fell in the combined group. The right ventricle showed improved function on echocardiography. This is the first demonstration that mitochondrial transfer from MSCs — not the cells themselves, not their secretome, but their organelles — can remodel the PAH lung and protect the right heart.
Clinical Trial Landscape: Where Does PAH Cell Therapy Stand in 2026?
The preclinical signal is loud. The clinical reality is quieter but not silent:
| Trial | Cell Type | Phase | Status | Key Detail |
|---|---|---|---|---|
| NCT04055415 | Adipose-derived MSCs | Phase 1/2 | Unknown (last update 2019) | Liaocheng People’s Hospital, China — first dedicated PAH MSC trial |
| NCT07542067 | Wharton’s jelly MSCs | Phase 1/2 | COMPLETED | Systemic sclerosis with refractory pulmonary involvement — Fundación Neumológica Colombiana |
| NCT07368088 | PNEUMOSTEM® (UC-MSC) | Phase 1 | NOT YET RECRUITING | Premature infants with early PAH — Samsung Medical Center, starting March 2026 |
The gap between preclinical and clinical is stark. PAH is rare (prevalence ~15–50 per million), and recruiting for cell therapy trials in a disease where patients are already on complex polypharmacy is logistically challenging. The HO-1 modification and mitochondrial transplantation approaches have not yet reached human testing. But the trajectory is clear: three independent mechanism papers in the first half of 2026 — each from different institutions, targeting different nodes in the PAH cascade (HO-1/MAPK, SOCS3/STAT3, mitochondrial bioenergetics) — converge on the same conclusion: MSCs are doing something vasodilators cannot.
What This Means for the PAH Patient
At our clinic, we see patients who have been told there is nothing else. They are on triple therapy, their six-minute walk distance is declining, and they are facing a transplant evaluation. The 2026 data does not yet offer an approved MSC treatment for PAH — no regulatory agency has authorized one. But the science is moving faster than the guidelines. The three mechanisms described here — HO-1 endothelial protection, SOCS3 fibroblast silencing, mitochondrial rescue — are not competing hypotheses; they are complementary modes of action that could, in principle, be combined in a single therapeutic strategy.
The next 24 months will be decisive. If NCT07368088 (PNEUMOSTEM®) reports safety data in neonates, and if the HO-1-modified MSCs progress to a first-in-human protocol, PAH could join the growing list of conditions — from diabetic kidney disease to multiple sclerosis to peripheral arterial disease — where mesenchymal stem cells are moving from bench to bedside. For now, the message is this: the vascular remodeling that kills PAH patients is no longer therapeutically untouchable.
Frequently Asked Questions
Can stem cells cure pulmonary arterial hypertension?
No cell therapy has demonstrated a cure for PAH in human trials to date. However, the 2026 preclinical evidence shows MSCs can reverse three core pathological processes — endothelial dysfunction, adventitial fibrosis, and mitochondrial failure — that current vasodilator drugs do not address. The goal is disease modification, not cure: slowing or halting the progressive vascular obliteration that defines PAH.
What is the difference between HO-1-modified MSCs and regular MSCs?
HO-1 (heme oxygenase-1) is a stress-response enzyme that degrades pro-oxidant heme into biliverdin, carbon monoxide, and free iron — all of which have signaling roles in vasodilation, anti-inflammation, and anti-apoptosis. PAH lungs are deficient in HO-1, particularly in the endothelium. Engineering MSCs to overexpress HO-1 amplifies their antioxidant, anti-inflammatory, and endothelial-protective capacity beyond what unmodified MSCs can achieve. The 2026 Stem Cells Translational Medicine study showed MSCs-HO-1 outperformed both unmodified MSCs and HO-1 monotherapy on every endpoint.
Are there any MSC clinical trials for PAH I can join?
As of August 2026, NCT07368088 (PNEUMOSTEM® for premature infants with early PAH) is the only recruiting trial at Samsung Medical Center in Seoul, and it is not yet actively enrolling. The dedicated adipose-derived MSC trial NCT04055415 in China has an unknown status with no recent updates. Patients interested in MSC therapy for pulmonary conditions should consult with a regenerative medicine specialist to discuss whether an expanded-access protocol or a related trial (e.g., for pulmonary fibrosis or systemic sclerosis-associated PAH) may be appropriate.
How do mitochondrial transplants from MSCs work?
Mitochondria are isolated from donor MSCs and infused intravenously. The organelles are taken up by recipient cells — primarily in the lung and right ventricle — where they integrate into the endogenous mitochondrial network and restore oxidative phosphorylation capacity. In the 2026 study by Onofre et al. (Int J Mol Sci, DOI: 10.3390/ijms27041761), mitochondrial transplantation from BM-MSCs specifically rescued Complex IV activity that sildenafil alone could not improve, suggesting a complementary mechanism to standard PAH therapy.
Why does a single MSC dose work better than repeated doses in some models?
The 2026 Wang et al. study (Stem Cell Res Ther, DOI: 10.1186/s13287-025-04883-5) found that a single early MSC infusion was more effective than repeated dosing in the MCT-PAH rat model. The likely explanation is that MSCs act early in the disease cascade — suppressing adventitial fibroblast activation via SOCS3/STAT3 before irreversible collagen deposition occurs. Once the fibrotic matrix is laid down, paracrine factors face a structural barrier. This finding reinforces the importance of early intervention in PAH and may explain why later-stage human trials have been less dramatic than preclinical data predicted.
References
1. Chen R, Chen X, Liang L, et al. HO-1-modified umbilical cord MSCs alleviate pulmonary arterial hypertension by reducing inflammation and endothelial dysfunction. Stem Cells Transl Med. 2026;15(7):szag036. DOI: 10.1093/stcltm/szag036
2. Wang J, Jin J, Zhang M, et al. Mesenchymal stromal cells alleviate pulmonary arterial hypertension by suppressing pulmonary arterial adventitial fibroblast activation and extracellular matrix remodeling via the SOCS3/STAT3 pathway. Stem Cell Res Ther. 2026;17(1):67. DOI: 10.1186/s13287-025-04883-5
3. Onofre MESF, Santos RT, Rocha NN, et al. Mitochondrial transplantation from bone marrow mesenchymal stromal cells combined with sildenafil attenuated vascular remodeling and improved right ventricular dysfunction in experimental PAH. Int J Mol Sci. 2026;27(4):1761. DOI: 10.3390/ijms27041761
4. Chen X, Su J, Liu H, et al. Endothelial-to-mesenchymal transition mechanisms in vascular remodeling of pulmonary hypertension. Int J Mol Sci. 2026;27(11):4951. DOI: 10.3390/ijms27114951
5. Chen R, et al. Tracheal delivery of HO-1-modified human umbilical cord-derived MSCs treats PAH by enhancing endothelial function through the MCP-1/ERK/NFAT pathway. Transl Res. 2026;Sep. DOI: 10.1016/j.trsl.2026.06.015
6. Li A, Wang X, Wu J, et al. Mesenchymal stem cells and derived extracellular vesicles in major respiratory diseases: from multifaceted molecular mechanisms to clinical perspectives. Front Cell Dev Biol. 2026;14:1839015. DOI: 10.3389/fcell.2026.1839015
7. ClinicalTrials.gov. NCT04055415, NCT07542067, NCT07368088. Accessed August 2026.